Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
41.59
USD
|
-0.60%
|
|
+2.24%
|
-17.79%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
8,497
|
7,906
|
4,297
|
5,365
|
7,258
|
6,066
|
-
|
-
|
Enterprise Value (EV)
1 |
8,602
|
8,047
|
4,649
|
4,561
|
6,157
|
5,955
|
6,284
|
6,391
|
P/E ratio
|
29
x
|
-17.5
x
|
-152
x
|
-19.9
x
|
-19.8
x
|
-10.5
x
|
-12.4
x
|
-21.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
7.57
x
|
10.8
x
|
5.3
x
|
9.14
x
|
9.21
x
|
9.75
x
|
7.85
x
|
5.51
x
|
EV / Revenue
|
7.66
x
|
11
x
|
5.74
x
|
7.77
x
|
7.81
x
|
9.57
x
|
8.13
x
|
5.8
x
|
EV / EBITDA
|
22.7
x
|
-50.7
x
|
35.6
x
|
-11.5
x
|
-18
x
|
-11.3
x
|
-11.9
x
|
-23.8
x
|
EV / FCF
|
27.3
x
|
10.4
x
|
247
x
|
-15.7
x
|
-18.6
x
|
-11.9
x
|
-13.4
x
|
-26.1
x
|
FCF Yield
|
3.66%
|
9.59%
|
0.41%
|
-6.36%
|
-5.38%
|
-8.39%
|
-7.44%
|
-3.82%
|
Price to Book
|
5.12
x
|
9.39
x
|
5.57
x
|
9.37
x
|
18.9
x
|
-115
x
|
-11.4
x
|
-9.76
x
|
Nbr of stocks (in thousands)
|
140,663
|
139,823
|
141,210
|
142,050
|
143,472
|
145,846
|
-
|
-
|
Reference price
2 |
60.41
|
56.54
|
30.43
|
37.77
|
50.59
|
41.59
|
41.59
|
41.59
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/24/22
|
2/22/23
|
2/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,123
|
729
|
810
|
587
|
788
|
622.3
|
772.9
|
1,101
|
EBITDA
1 |
378.4
|
-158.7
|
130.5
|
-395.9
|
-342.7
|
-526.7
|
-528.3
|
-268
|
EBIT
1 |
366
|
-172
|
-30
|
-411
|
-353
|
-578.4
|
-481.2
|
-280.4
|
Operating Margin
|
32.59%
|
-23.59%
|
-3.7%
|
-70.02%
|
-44.8%
|
-92.94%
|
-62.25%
|
-25.47%
|
Earnings before Tax (EBT)
1 |
347
|
-170
|
-30
|
-258
|
-334
|
-601.7
|
-526.6
|
-322.5
|
Net income
1 |
294
|
-451
|
-29
|
-270
|
-366
|
-573.3
|
-495.7
|
-285.2
|
Net margin
|
26.18%
|
-61.87%
|
-3.58%
|
-46%
|
-46.45%
|
-92.12%
|
-64.13%
|
-25.9%
|
EPS
2 |
2.080
|
-3.230
|
-0.2000
|
-1.900
|
-2.560
|
-3.974
|
-3.355
|
-1.909
|
Free Cash Flow
1 |
314.8
|
772
|
18.84
|
-290.1
|
-331.3
|
-499.5
|
-467.4
|
-244.4
|
FCF margin
|
28.03%
|
105.9%
|
2.33%
|
-49.42%
|
-42.05%
|
-80.25%
|
-60.47%
|
-22.2%
|
FCF Conversion (EBITDA)
|
83.19%
|
-
|
14.44%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
107.08%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/24/22
|
2/22/23
|
2/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
133
|
440
|
142
|
134
|
160
|
152
|
131
|
188
|
144
|
325
|
138.6
|
144.5
|
164.7
|
173.8
|
143.2
|
EBITDA
1 |
-82.14
|
247.8
|
-53.8
|
-81.73
|
-55.34
|
-205
|
-111.4
|
-
|
-140.7
|
-3.456
|
-152.1
|
-155.2
|
-97.15
|
-104.3
|
-
|
EBIT
1 |
-86
|
221
|
-57
|
-86
|
-59
|
-208
|
-114
|
-91
|
-143
|
-6
|
-156.1
|
-158.9
|
-142.3
|
-147.9
|
-178
|
Operating Margin
|
-64.66%
|
50.23%
|
-40.14%
|
-64.18%
|
-36.88%
|
-136.84%
|
-87.02%
|
-48.4%
|
-99.31%
|
-1.85%
|
-112.62%
|
-109.95%
|
-86.44%
|
-85.09%
|
-124.3%
|
Earnings before Tax (EBT)
1 |
-84
|
225
|
-64
|
-103
|
-47
|
-44
|
-113
|
-77
|
-141
|
-3
|
-157.9
|
-163
|
-145.1
|
-145.5
|
-191.8
|
Net income
1 |
-82
|
225
|
-65
|
-105
|
-47
|
-52
|
-124
|
-85
|
-147
|
-9
|
-154.6
|
-159.5
|
-144.3
|
-145.5
|
-192.5
|
Net margin
|
-61.65%
|
51.14%
|
-45.77%
|
-78.36%
|
-29.38%
|
-34.21%
|
-94.66%
|
-45.21%
|
-102.08%
|
-2.77%
|
-111.57%
|
-110.39%
|
-87.65%
|
-83.75%
|
-134.4%
|
EPS
2 |
-0.5800
|
1.410
|
-0.4600
|
-0.7400
|
-0.3300
|
-0.3700
|
-0.8700
|
-0.6000
|
-1.030
|
-0.0600
|
-1.056
|
-1.054
|
-0.9811
|
-1.024
|
-1.307
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/3/21
|
2/24/22
|
5/4/22
|
8/9/22
|
11/9/22
|
2/22/23
|
5/3/23
|
8/9/23
|
11/2/23
|
2/21/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
104
|
141
|
352
|
-
|
-
|
-
|
218
|
325
|
Net Cash position
1 |
-
|
-
|
-
|
804
|
1,102
|
111
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.2755
x
|
-0.8912
x
|
2.697
x
|
-
|
-
|
-
|
-0.4131
x
|
-1.213
x
|
Free Cash Flow
1 |
315
|
772
|
18.8
|
-290
|
-331
|
-499
|
-467
|
-244
|
ROE (net income / shareholders' equity)
|
23.4%
|
-3.88%
|
-3.78%
|
-40.1%
|
-76.3%
|
-277%
|
-11.5%
|
-186%
|
ROA (Net income/ Total Assets)
|
9.97%
|
-4.4%
|
-1.14%
|
-10.5%
|
-13.3%
|
-35.1%
|
-35%
|
-6.6%
|
Assets
1 |
2,949
|
10,245
|
2,536
|
2,575
|
2,760
|
1,633
|
1,418
|
4,321
|
Book Value Per Share
2 |
11.80
|
6.020
|
5.470
|
4.030
|
2.680
|
-0.3600
|
-3.650
|
-4.260
|
Cash Flow per Share
2 |
2.420
|
0.2600
|
0.2200
|
-1.930
|
-2.150
|
-2.490
|
-1.840
|
0.8500
|
Capex
1 |
30.9
|
35.1
|
12
|
15.7
|
23.8
|
23.7
|
27.9
|
29.7
|
Capex / Sales
|
2.75%
|
4.82%
|
1.48%
|
2.68%
|
3.02%
|
3.81%
|
3.6%
|
2.7%
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/24/22
|
2/22/23
|
2/21/24
|
-
|
-
|
-
|
Last Close Price
41.59
USD Average target price
58.13
USD Spread / Average Target +39.77% Consensus |
1st Jan change
|
Capi.
|
---|
| -17.79% | 6.07B | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|